語系:
繁體中文
English
說明(常見問題)
登入
回首頁
切換:
標籤
|
MARC模式
|
ISBD
Drug adherence in hypertension and c...
~
SpringerLink (Online service)
Drug adherence in hypertension and cardiovascular protection
紀錄類型:
書目-語言資料,印刷品 : Monograph/item
正題名/作者:
Drug adherence in hypertension and cardiovascular protection/ edited by Michel Burnier.
其他作者:
Burnier, Michel.
出版者:
Cham :Springer International Publishing : : 2018.,
面頁冊數:
viii, 314 p. :digital ; : 24 cm.;
Contained By:
Springer eBooks
標題:
Patient compliance. -
電子資源:
http://dx.doi.org/10.1007/978-3-319-76593-8
ISBN:
9783319765938
Drug adherence in hypertension and cardiovascular protection
Drug adherence in hypertension and cardiovascular protection
[electronic resource] /edited by Michel Burnier. - Cham :Springer International Publishing :2018. - viii, 314 p. :digital ;24 cm. - Updates in hypertension and cardiovascular protection,2366-4606. - Updates in hypertension and cardiovascular protection..
1 Taxonomy of adherence -- I Measuring drug adherence -- 2 Qualitative assessment of adherence -- 3 Electronic monitoring of drug adherence -- 4 Measurements of drugs in plasma/urine -- 5 Assessing adherence measurement in large databases -- 6 Direct observed treatment in hypertension -- 7 Novel technologies for following drug adherence -- 8 Ethical aspects of measuring adherence II Risk factors for non-adherence -- 9 Determinants and barriers to adherence in CV diseases -- 10 Beliefs and adherence -- III Adherence in hypertension and CV protection -- 11 Impact of drug adherence in clinical trials -- 12 Drug adherence in essential hypertension: impact of drugs -- 13 Persistence in hypertension in general practice -- 14 Drug adherence in resistant hypertension -- 15 Drug adherence with cardiovascular medicines (statins) -- 16 Adherence and cardiovascular risk -- IV Interventions to improve drug adherence -- 17 Which interventions are useful? -- 18 Use of fixed-dose combinations in CV disease prevention -- 19 Nurse-led intervention in Hypertension -- 20 Role of the Pharmacist in supporting adherence -- 21 Integrated approaches to support adherence -- 22 Use of Apps to improve drug adherence -- V Health care consequences of non-adherence -- 23 Global clinical consequence of poor adherence -- 24 Cost of non-adherence.
This book provides a critical and comprehensive review of the methodologies available for measuring drug adherence in clinical practice, including those relying on emerging technologies. The authors discuss the risk factors of non-adherence and shed light on how to identify patients at risk of poor adherence. Drug therapies in chronic diseases rely heavily on the patient's adherence, since drugs that are not taken are ineffective and leave the patient at high risk of developing clinical complications. Given the absence of new drugs for the treatment of hypertension, drug adherence is particularly important in these patients to improve blood pressure control. The book further investigates a new aspect, namely the importance of drug adherence in clinical trials and studies and draws attention to the limits of developing drugs without significant information on drug adherence. Several chapters are dedicated to the importance of adherence in specific forms of hypertension, such as resistant hypertension, dyslipidemia and hypertension associated with cardiovascular risk. As experts confronted with drug adherence in their daily practice, the authors analyse the real effectiveness of several interventions aimed at improving drug adherence and put particular emphasis on the importance of an interdisciplinary approach involving nurses and pharmacists. The volume also includes a careful analysis of the health and economic impact of poor adherence. The book is aimed at physicians, pharmacists, students and all health professionals dealing not only with hypertension or dyslipidemia, but also with chronic asymptomatic diseases such as diabetes, HIV or chronic respiratory diseases.
ISBN: 9783319765938
Standard No.: 10.1007/978-3-319-76593-8doiSubjects--Topical Terms:
1065904
Patient compliance.
LC Class. No.: R727.43 / .D784 2018
Dewey Class. No.: 615.5
Drug adherence in hypertension and cardiovascular protection
LDR
:04049nam a2200325 a 4500
001
927344
003
DE-He213
005
20190111135742.0
006
m d
007
cr nn 008maaau
008
190626s2018 gw s 0 eng d
020
$a
9783319765938
$q
(electronic bk.)
020
$a
9783319765921
$q
(paper)
024
7
$a
10.1007/978-3-319-76593-8
$2
doi
035
$a
978-3-319-76593-8
040
$a
GP
$c
GP
041
0
$a
eng
050
4
$a
R727.43
$b
.D784 2018
072
7
$a
MJD
$2
bicssc
072
7
$a
MED010000
$2
bisacsh
082
0 4
$a
615.5
$2
23
090
$a
R727.43
$b
.D794 2018
245
0 0
$a
Drug adherence in hypertension and cardiovascular protection
$h
[electronic resource] /
$c
edited by Michel Burnier.
260
$a
Cham :
$c
2018.
$b
Springer International Publishing :
$b
Imprint: Springer,
300
$a
viii, 314 p. :
$b
digital ;
$c
24 cm.
490
1
$a
Updates in hypertension and cardiovascular protection,
$x
2366-4606
505
0
$a
1 Taxonomy of adherence -- I Measuring drug adherence -- 2 Qualitative assessment of adherence -- 3 Electronic monitoring of drug adherence -- 4 Measurements of drugs in plasma/urine -- 5 Assessing adherence measurement in large databases -- 6 Direct observed treatment in hypertension -- 7 Novel technologies for following drug adherence -- 8 Ethical aspects of measuring adherence II Risk factors for non-adherence -- 9 Determinants and barriers to adherence in CV diseases -- 10 Beliefs and adherence -- III Adherence in hypertension and CV protection -- 11 Impact of drug adherence in clinical trials -- 12 Drug adherence in essential hypertension: impact of drugs -- 13 Persistence in hypertension in general practice -- 14 Drug adherence in resistant hypertension -- 15 Drug adherence with cardiovascular medicines (statins) -- 16 Adherence and cardiovascular risk -- IV Interventions to improve drug adherence -- 17 Which interventions are useful? -- 18 Use of fixed-dose combinations in CV disease prevention -- 19 Nurse-led intervention in Hypertension -- 20 Role of the Pharmacist in supporting adherence -- 21 Integrated approaches to support adherence -- 22 Use of Apps to improve drug adherence -- V Health care consequences of non-adherence -- 23 Global clinical consequence of poor adherence -- 24 Cost of non-adherence.
520
$a
This book provides a critical and comprehensive review of the methodologies available for measuring drug adherence in clinical practice, including those relying on emerging technologies. The authors discuss the risk factors of non-adherence and shed light on how to identify patients at risk of poor adherence. Drug therapies in chronic diseases rely heavily on the patient's adherence, since drugs that are not taken are ineffective and leave the patient at high risk of developing clinical complications. Given the absence of new drugs for the treatment of hypertension, drug adherence is particularly important in these patients to improve blood pressure control. The book further investigates a new aspect, namely the importance of drug adherence in clinical trials and studies and draws attention to the limits of developing drugs without significant information on drug adherence. Several chapters are dedicated to the importance of adherence in specific forms of hypertension, such as resistant hypertension, dyslipidemia and hypertension associated with cardiovascular risk. As experts confronted with drug adherence in their daily practice, the authors analyse the real effectiveness of several interventions aimed at improving drug adherence and put particular emphasis on the importance of an interdisciplinary approach involving nurses and pharmacists. The volume also includes a careful analysis of the health and economic impact of poor adherence. The book is aimed at physicians, pharmacists, students and all health professionals dealing not only with hypertension or dyslipidemia, but also with chronic asymptomatic diseases such as diabetes, HIV or chronic respiratory diseases.
650
0
$a
Patient compliance.
$3
1065904
650
0
$a
Hypertension
$x
Chemotherapy.
$3
1206582
650
1 4
$a
Medicine & Public Health.
$3
593949
650
2 4
$a
Cardiology.
$3
593957
650
2 4
$a
Pharmacotherapy.
$3
973587
650
2 4
$a
Angiology.
$3
668966
650
2 4
$a
Metabolic Diseases.
$3
593967
650
2 4
$a
Diabetes.
$3
582755
700
1
$a
Burnier, Michel.
$3
1206581
710
2
$a
SpringerLink (Online service)
$3
593884
773
0
$t
Springer eBooks
830
0
$a
Updates in hypertension and cardiovascular protection.
$3
1110744
856
4 0
$u
http://dx.doi.org/10.1007/978-3-319-76593-8
950
$a
Medicine (Springer-11650)
筆 0 讀者評論
多媒體
評論
新增評論
分享你的心得
Export
取書館別
處理中
...
變更密碼[密碼必須為2種組合(英文和數字)及長度為10碼以上]
登入